IL323175A - Human complement component 2 binding molecules - Google Patents

Human complement component 2 binding molecules

Info

Publication number
IL323175A
IL323175A IL323175A IL32317525A IL323175A IL 323175 A IL323175 A IL 323175A IL 323175 A IL323175 A IL 323175A IL 32317525 A IL32317525 A IL 32317525A IL 323175 A IL323175 A IL 323175A
Authority
IL
Israel
Prior art keywords
seq
human
amino acid
acid sequence
complement
Prior art date
Application number
IL323175A
Other languages
English (en)
Hebrew (he)
Original Assignee
Cleveland Clinic Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cleveland Clinic Found filed Critical Cleveland Clinic Found
Publication of IL323175A publication Critical patent/IL323175A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Rehabilitation Therapy (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL323175A 2023-03-07 2025-09-04 Human complement component 2 binding molecules IL323175A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363488825P 2023-03-07 2023-03-07
PCT/US2024/018604 WO2024186861A2 (en) 2023-03-07 2024-03-06 Human complement component 2 binding molecules

Publications (1)

Publication Number Publication Date
IL323175A true IL323175A (en) 2025-11-01

Family

ID=92675651

Family Applications (1)

Application Number Title Priority Date Filing Date
IL323175A IL323175A (en) 2023-03-07 2025-09-04 Human complement component 2 binding molecules

Country Status (7)

Country Link
EP (1) EP4676952A2 (de)
JP (1) JP2026509811A (de)
KR (1) KR20250158059A (de)
CN (1) CN121443634A (de)
AU (1) AU2024234014A1 (de)
IL (1) IL323175A (de)
WO (1) WO2024186861A2 (de)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2584105B (en) * 2019-05-21 2023-08-02 Argenx Bvba Methods of treating neuropathy
CN116217728A (zh) * 2019-09-10 2023-06-06 普米斯生物技术(珠海)有限公司 靶向caix抗原的纳米抗体及其应用
CN116438456A (zh) * 2020-09-11 2023-07-14 格里姆普斯生物股份有限公司 用于疾病检测/诊断、分期、监测和治疗的离体蛋白酶活性检测

Also Published As

Publication number Publication date
JP2026509811A (ja) 2026-03-25
CN121443634A (zh) 2026-01-30
WO2024186861A2 (en) 2024-09-12
AU2024234014A1 (en) 2025-10-23
WO2024186861A3 (en) 2024-10-17
KR20250158059A (ko) 2025-11-05
EP4676952A2 (de) 2026-01-14

Similar Documents

Publication Publication Date Title
DK2097455T3 (en) HUMANIZED ANTI-FACTOR D ANTIBODIES
KR102662387B1 (ko) B7-h3 항체, 이의 항원-결합 단편 및 이의 의학적 용도
US11713354B2 (en) Galectin-10 antibodies
US9243070B2 (en) Humanized and chimeric anti-factor Bb antibodies and uses thereof
JP2023120208A (ja) 補体成分ｃ５または血清アルブミンと結合するポリペプチドおよびその融合タンパク質
JP2022516848A (ja) Ｂｔｎ３ａ結合タンパク質及びその使用
US20240209114A1 (en) Anti-masp2 antibody, antigen-binding fragment thereof and medical use thereof
Chen et al. A nanobody-based complement inhibitor targeting complement component 2 reduces hemolysis in a complement humanized mouse model of autoimmune hemolytic anemia
WO2023016516A1 (zh) 抗vegf a和vegf c双特异性抗体及其用途
US20250059285A1 (en) Galectin-10 antibodies
WO2022037528A1 (zh) 结合bcma的单可变结构域及抗原结合分子
CN114502583A (zh) 补体c2结合蛋白及其用途
CN113880951A (zh) 凝血因子xi(fxi)结合蛋白
AU2024234014A1 (en) Human complement component 2 binding molecules
CN115803348B (zh) 凝血因子xi(fxi)结合蛋白
CN119409815B (zh) 抗人补体c5 vhh抗体及其应用
JP7735545B2 (ja) Ｃｄｃプラットホーム抗体
US20250066508A1 (en) Anti-masp-2 antibody, preparation method therefor, and application thereof
WO2024188179A1 (zh) 一种靶向ctgf的抗体或其抗原结合片段及其应用
WO2025119329A1 (zh) 抗c5和htra1双特异性抗体及其用途
WO2025113639A1 (zh) 抗gdf15的抗体及其方法和用途
HK40084746A (en) Coagulation factor xi (fxi) binding protein
HK40049006B (en) Anti-gpc3 antibody, antigen-binding fragment thereof, and medical use thereof